


## Supplementary data

**Figure S1.** Progression-free survival according to treatment feasibility in the metastatic colorectal population.



**Table S1.** Chemotherapy feasibility after planned 3 months schedule completion

	All	Colorectal cancer	Pancreatic cancer	Lung cancer	Breast cancer	Ovarian cancer	Others
	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
<b>Chemotherapy feasibility after planned 3 months schedule completion</b>							
No	218 (42.2)	100 (38.3)	26 (47.3)	21 (55.3)	11 (31.4)	13 (38.2)	47 (50.5)
Yes	298 (57.7)	161 (61.7)	29 (52.7)	17 (44.7)	24 (68.6)	21 (61.7)	46 (49.5)
<i>Treatment</i>							
Targeted therapy	40 (7.7)	32 (12.3)	0 (0.0)	0 (0.0)	7 (20)	0 (0.0)	1 (1.1)
Monochemotherapy	198 (38.4)	82 (31.4)	50 (90.9)	9 (23.7)	23 (65.7)	6 (17.6)	28 (30.1)
Fluoropyrimidines	84 (42.4)	79 (96.3)	0 (0.0)	0 (0.0)	4 (17.4)	0 (0.0)	3 (10.7)
Gemcitabine	57 (28.8)	0 (0.0)	50 (100)	4 (44.4)	0 (0.0)	0 (0.0)	3 (10.7)
Docetaxel	17 (8.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)	16 (57.1)
Paclitaxel	15 (7.6)	0 (0.0)	0 (0.0)	1 (11.1)	12 (6.1)	0 (0.0)	2 (7.1)
Carboplatin	10 (5.0)	0 (0.0)	0 (0.0)	2 (22.2)	0 (0.0)	6 (100)	2 (7.1)
Other	15 (7.6)	3 (3.6)	0 (0.0)	2 (22.2)	6 (3.0)	0 (0.0)	4 (14.3)
≥ Doublet chemotherapy	313 (60.6)	176 (67.4)	5 (9.1)	29 (76.3)	12 (34.3)	28 (82.3)	63 (67.7)
FOLFOX/XELOX	153 (48.9)	135 (76.7)	2 (40.0)	0 (0.0)	2 (16.7)	0 (0.0)	14 (22.2)
FOLFIRI	43 (13.7)	37 (21.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6 (9.5)
Carboplatin-paclitaxel	43 (13.7)	0 (0.0)	0 (0.0)	9 (31.0)	0 (0.0)	27 (96.4)	7 (7.5)
Other	73 (23.3)	7 (3.9)	3 (60.0)	20 (68.9)	10 (83.3)	1 (3.6)	32 (50.8)
Unknown	1 (0.3)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.2)
Other	5 (1.6)	3 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.2)
<i>Toxicity</i>							
Grade < 3/4	350 (67.8)	188 (72.0)	35 (63.6)	19 (50.0)	22 (62.8)	23 (67.6)	63 (67.7)
Grade 3/4	123 (23.8)	58 (22.2)	16 (29.1)	8 (21.0)	7 (20.0)	10 (29.4)	24 (25.8)
Unknown	43 (8.3)	15 (5.7)	4 (7.3)	11 (28.9)	6 (17.1)	1 (2.9)	6 (6.4)
<i>Response*</i>							
No.	<i>N</i> = 357	<i>N</i> = 189	<i>N</i> = 33	<i>N</i> = 23	<i>N</i> = 24	<i>N</i> = 30	<i>N</i> = 58
CR+PR	110 (30.8)	57 (30.2)	5 (15.1)	9 (39.1)	6 (25.0)	16 (53.3)	17 (29.3)
SD	157 (42.6)	83 (43.9)	18 (54.5)	7 (30.4)	14 (58.3)	10 (33.3)	25 (43.1)
PD	81 (22.7)	32 (16.9)	17 (51.5)	7 (30.4)	5 (20.8)	3 (10.0)	17 (29.3)
Unknown/Not available	168 (47.1)	89 (47.1)	15 (45.4)	15 (65.2)	10 (41.7)	5 (16.7)	34 (58.6)

Abbreviations: FOLFOX: leucovorin, 5-fluorouracil, and oxaliplatin; XELOX: oxaliplatin plus capecitabine; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease

\* In advanced population

**Table S2.** Adverse events in the whole and colorectal cancer populations

Toxicity	All		Colorectal cancer population	
	N = 516		N = 261	
	Grade 1-2	Grade 3-5	Grade 1-2	Grade 3-5
	No. (%)	No. (%)	No. (%)	No. (%)
Neutrophils	98 (19.0)	46 (8.9)	47 (9.1)	23 (4.4)
Hemoglobin	291 (56.4)	15 (2.9)	148 (28.7)	4 (0.8)
Platelets	133 (25.8)	12 (2.3)	71 (13.7)	6 (1.2)
Nausea	130 (25.2)	5 (1.0)	70 (13.6)	2 (0.4)
Vomiting	64 (12.4)	5 (1.0)	36 (7.0)	2 (0.4)
Mucositis	62 (12.0)	4 (0.8)	42 (8.1)	0 (0.0)
Hand-foot syndrome	23 (4.4)	4 (0.8)	11 (2.1)	2 (0.4)
Neuropathy	118 (22.9)	3 (0.6)	90 (17.4)	3 (0.6)
Alopecia	68 (13.2)	0 (0.0)	26 (5.0)	0 (0.0)
Creatinine	71 (13.7)	5 (1.0)	42 (8.1)	1 (0.2)
Diarrhea	116 (22.5)	13 (2.5)	78 (15.1)	9 (1.7)
Other	42 (8.1)	42 (8.1)	33 (6.4)	18 (3.5)
Maximal toxicity	303 (58.7)	124 (24.0)	165 (32.0)	60 (11.6)

**Table S3.** Adverse events according to the feasibility of treatment in the whole and colorectal cancer populations.

	<b>All</b>				<b>Colorectal cancer</b>			
<b>Toxicity</b>	<b>N = 516</b>				<b>N = 261</b>			
	<b>Grade 0-2</b>		<b>Grade 3-5</b>		<b>Grade 0-2</b>		<b>Grade 3-5</b>	
	<b>Treatment</b>							
	<b>Feasible n = 298</b>	<b>Unfeasible n = 218</b>	<b>Feasible n = 298</b>	<b>Unfeasible n = 218</b>	<b>Feasible n = 161</b>	<b>Unfeasible n = 100</b>	<b>Feasible n = 161</b>	<b>Unfeasible n = 100</b>
	<b>No. (%)</b>	<b>No. (%)</b>						
Neutrophils	213 (71.5)	159 (53.3)	33 (11.1)	13 (4.4)	125 (77.6)	20 (12.4)	79 (49.1)	3 (1.9)
Hemoglobin	244 (81.9)	171 (57.4)	11 (3.7)	4 (1.3)	144 (89.4)	2 (1.2)	79 (49.1)	2 (1.2)
Platelets	241 (80.9)	169 (56.7)	10 (3.3)	2 (0.7)	139 (86.3)	6 (3.7)	80 (49.7)	0 (0.0)
Nausea	268 (89.9)	196 (65.8)	4 (1.3)	1 (0.3)	153 (95.0)	1 (0.6)	91 (56.5)	1 (0.6)
Vomiting	271 (90.9)	193 (64.8)	1 (0.3)	4 (1.3)	153 (95.0)	1 (0.6)	91 (56.5)	1 (0.6)
Mucositis	269 (90.3)	196 (65.8)	3 (1.0)	1 (0.3)	154 (95.6)	0 (0.0)	92 (57.1)	0 (0.0)
Hand-foot syndrome	264 (88.6)	197 (66.1)	4 (1.3)	0 (0.0)	150 (93.2)	2 (1.2)	92 (57.1)	0 (0.0)
Neuropathy	271 (90.9)	195 (65.4)	1 (0.3)	2 (0.7)	153 (95.0)	1 (0.6)	90 (55.9)	2 (1.2)
Alopecia	267 (89.6)	196 (65.8)	0 (0.0)	0 (0.0)	152 (94.4)	0 (0.0)	92 (57.1)	0 (0.0)
Neutropenia	242 (81.2)	166 (55.7)	4 (1.3)	4 (1.3)	140 (86.9)	4 (2.5)	80 (49.7)	1 (0.6)
Creatinine	242 (81.2)	158 (53.0)	2 (0.7)	3 (1.0)	142 (88.2)	0 (0.0)	74 (46.0)	1 (0.6)
Diarrhea	269 (90.3)	188 (63.1)	4 (1.3)	9 (3.0)	150 (93.2)	4 (2.5)	87 (54.0)	5 (3.1)
Other	239 (80.2)	173 (58.0)	23 (7.7)	19 (6.4)	139 (86.3)	10 (6.2)	77 (47.8)	8 (5.0)
Maximal toxicity	195 (65.4)	154 (51.7)	79 (26.5)	45 (15.1)	111 (68.9)	43 (26.7)	75 (46.6)	17 (10.5)

**Table S4.** Adverse events according to chemotherapy regimen in the colorectal population.

	Mono chemotherapy		FOLFIRI		Oxaliplatin-based chemotherapy (FOLFOX, XELOX)		Other	
	Grade 1-2 No. (%)	Grade 3-5 No. (%)	Grade 1-2 No. (%)	Grade 3-5 No. (%)	Grade 1-2 No. (%)	Grade 3-5 No. (%)	Grade 1-2 No. (%)	Grade 3-5 No. (%)
Neutrophils	6 (2.3)	2 (0.8)	6 (2.3)	5 (1.9)	33 (12.6)	15 (5.7)	1 (0.4)	1 (0.4)
Hemoglobin	31 (11.9)	1 (0.4)	18 (6.9)	0 (0.0)	95 (36.4)	2 (0.8)	4 (1.5)	1 (0.4)
Platelets	4 (1.5)	1 (0.4)	2 (0.8)	0 (0.0)	61 (23.4)	5 (1.9)	4 (1.5)	0 (0.0)
Nausea	18 (6.9)	1 (0.4)	9 (3.4)	0 (0.0)	41 (15.7)	1 (0.4)	1 (0.4)	0 (0.0)
Vomiting	8 (3.1)	1 (0.4)	5 (1.9)	0 (0.0)	22 (8.4)	1 (0.4)	1 (0.4)	0 (0.0)
Mucositis	11 (4.2)	0 (0.0)	2 (0.8)	0 (0.0)	28 (10.7)	0 (0.0)	1 (0.4)	0 (0.0)
Hand-foot syndrome	3 (1.1)	1 (0.4)	2 (0.8)	0 (0.0)	6 (2.3)	1 (0.4)	0 (0.0)	0 (0.0)
Neuropathy	3 (1.1)	0 (0.0)	2 (0.8)	0 (0.0)	85 (32.6)	3 (1.1)	0 (0.0)	0 (0.0)
Alopecia	7 (2.7)	0 (0.0)	5 (1.9)	0 (0.0)	12 (4.6)	0 (0.0)	2 (0.8)	0 (0.0)
Neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	4 (1.5)	0 (0.0)	0 (0.0)
Increased creatinine	10 (3.8)	0 (0.0)	5 (1.9)	0 (0.0)	23 (8.8)	1 (0.4)	4 (1.5)	0 (0.0)
Diarrhea	14 (5.4)	1 (0.4)	11 (4.2)	4 (1.5)	50 (19.1)	4 (1.5)	2 (0.8)	0 (0.0)
Other	4 (1.5)	7 (2.7)	4 (1.5)	4 (1.5)	25 (9.6)	7 (2.7)	0 (0.0)	0 (0.0)

**Table A5.** Survival times according to treatment feasibility in the whole and metastatic colorectal cancer populations

Survival*	All	Unfeasibility group	Feasibility group	HR**	P
All tumors					
All stages	N = 516	N = 218	N = 298		
1-year OS rate (%)	66.6 (60.7-71.8)				
Median OS	17.8 (14.5-27.7)	8.4 (5.8-13.0)	18.6 (16.7-22.6)	0.62 (0.49-0.77)	< 0.001
Metastatic	N = 357	N = 159	N = 198		
Median OS	13.9 (11.5-16.7)	5.8 (4.1-9.9)	18.0 (16.1-21.4)	0.57 (0.44-0.74)	< 0.001
Median PFS	5.6 (4.7-6.7)	2.8 (2.5-3.3)	7.2 (6.3-8.7)	0.43 (0.32-0.58)	< 0.001
Colorectal cancer					
Metastatic	N = 189	N = 78	N = 111		
Median OS	16.3 (13.9-20.4)	9.9 (4.4-14.1)	18.6 (16.2-22.6)	0.70 (0.49-0.99)	0.033
Median PFS	6.3 (4.8-8.2)	3.4 (2.7-5.5)	7.4 (6.0-9.6)	0.55 (0.37-0.83)	0.002

Abbreviations: HR: hazard ration; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival

\*In months unless stated otherwise

\*\*Comparison of unfeasible (reference) versus feasible (HR < 1 favors "feasible")